AI emerging as another tool for drug development
Start-ups like Genesis Therapeutics are using various AI methods, including generative AI, to design new drug candidates.
Will the drugs that you take to address illnesses be developed using artificial intelligence (AI)? It seems that is a very distinct possibility, according to this recent article by Marina Temkin that was published by PitchBook.
Writing that “the use of large language and diffusion models to discover medicines is not widely discussed,” she notes that “there still aren’t many biotech start-ups that are employing generative AI methods to create novel drug compounds, (but) some early adopters have succeeded in raising substantive funding in recent months.”
One is Genesis Therapeutics, a biotechnology start-up that uses various AI methods, including generative AI, to design new drug candidates. The Burlingame, CA-based company recently raised a $200 million Series B co-led by Andreessen Horowitz.
Tempkin explains that “while the drugs designed by Genesis are not yet being tested in human trials, its computer-created compounds are showing promise. The company has been using generative AI in conjunction with predictive AI models since it spun out of Stanford University in 2019.”